C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | MicrobiomeTrials← Back to trialsNCT03635632
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2019-04-23Est. Completion: 2023-05-16
Enrollment target: 94 participants Locations- Houston Methodist Hospital, Houston, Texas, United States
- Texas Children's Hospital, Houston, Texas, United States
Other microbiome trials you might be interested in
Constitutional Mismatch Repair Deficiency SyndromeHematopoietic and Lymphoid Cell NeoplasmLynch SyndromeRecurrent LymphomaRecurrent Malignant Solid NeoplasmRecurrent NeuroblastomaRecurrent Primary Central Nervous System NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory NeuroblastomaRefractory Primary Central Nervous System NeoplasmXeroderma Pigmentosum
This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well th…
Palo Alto, United StatesCompleted Jun 21, 2022
Neuroblastoma
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinot…
Los Angeles, United StatesEst. completion Dec 2028
Neuroblastoma
The goal of this study is to demonstrate that cytokine-induced memory-like natural killer cells (CIML-NK cells) can be g…
Cincinnati, United StatesEst. completion Jun 2031